OGN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 5.09
- PEG ratio
- —
- P/B
- 3.90
- P/S (TTM)
- 0.57
- EV/EBITDA
- 7.89
Profitability & growth
- ROE (TTM)
- 34.1%
- Operating margin
- 18.7%
- Revenue growth YoY
- -3.5%
- Dividend yield
- 0.6%
- Beta
- 1.54
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Organon & Co
Company profileOrganon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 30 HUDSON STREET, JERSEY CITY, NJ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
